Global Cardiac Resynchronization Therapy Market to reach USD 5.8 billion by 2027. Global Cardiac Resynchronization Therapy Market is valued approximately at USD 4.3 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 4.4% over the forecast period 2021-2027. The major factors contributing to the growth of the CRT market are rising incidences of cardiac disorders and heart failure and shift towards a sedentary lifestyle among the population. The rise in geriatric population due to increased life expectancy is also fueling the market growth. According to the data of United Nations, the number of persons aged above 65 years was estimated to be 727 million in 2020 and the number is projected to be more than double by 2050. Also, the percentage of older people among the global population is anticipated to increase from 9.3 percent in 2020 to 16 percent in 2050. Furthermore, technological advancements and new emerging markets are likely to open up new opportunities for the market. However, lack of skilled professionals and high device replacement cost may hinder the growth of the market over the forecast period.

The regional analysis of global Cardiac Resynchronization Therapy Market is based on key regions including Asia Pacific, Europe, North America, Latin America, and the rest of the world. North America is dominating the market in terms of share and is also expected to exhibit the highest CAGR over the forecast period. This growth can be attributed to the growing healthcare expenditure, and the advent of new technological advancements in the region.

Major market player included in this report are:

Medtronic, PLC.
Abbott Laboratories
Boston Scientific Corporation
Biotronik
Medico S.P.A.
MicroPort Scientific Corporation
St. Jude Medical
LivaNova Plc
Lepu Medical Technology Co. Ltd.
Shree Pacetronix Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type:
Cardiac Resynchronized Therapy Defibrillators
Cardiac Resynchronized Therapy Pacemakers
By End User:
Hospitals & Cardiac Centers
Ambulatory Surgery Centers

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Cardiac Resynchronization Therapy Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors